A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection

PHASE1CompletedINTERVENTIONAL

Enrollment

119

Participants

Timeline

Start Date

June 21, 2022

Primary Completion Date

January 1, 2024

Study Completion Date

March 18, 2024

Conditions

Chronic Hepatitis B

Interventions

DRUG

LW231 tablets

P.O.

DRUG

Placebo

P.O.

Trial Locations (1)

The First Hospital of Jilin University, Changchun

All Listed Sponsors

lead

Shanghai Longwood Biopharmaceuticals Co., Ltd.

INDUSTRY